Virtual Library

Start Your Search

Kuruswamy Thurai Prasad

Author of

  • +

    EP1.01 - Advanced NSCLC (ID 150)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.01-57 - Clinical Profile and Treatment Outcomes of NSCLC in Elderly Subjects with Poor Performance Status from India (ID 1577)

      08:00 - 18:00  |  Author(s): Kuruswamy Thurai Prasad

      • Abstract
      • Slides


      Background: Elderly population and subjects with poor performance status (PS) are generally excluded from Lung cancer (LC) trials evaluating various treatment modalities, and their outcome is unclear. Herein, we report the clinical profile, treatment and overall survival (OS) of elderly non-small cell LC (NSCLC) subjects with poor PS.


      Methods: We retrospectively reviewed our database (from Jan 2016-Dec 2017) to identify NSCLC subjects aged ≥65 years and having an Eastern cooperative oncology group PS (ECOG-PS) ≥2 at presentation. Demographic profile, treatment details, PS after treatment and OS (as on 15th November 2018) were retrieved. We also report the incidence of grade 3 or 4 adverse events (AE) following chemotherapy.


      Results: 122 patients with a median (interquartile range [IQR]) age of 72.5 (65-88) years were included. Majority were men (86.1%) and smokers (79.5%). ECOG-PS was 2, 3 and 4 in 64.8%, 27.9% and 7.4% patients. Squamous cell carcinoma (53, 43.4%) and adenocarcinoma (51, 41.8%) were the most common histologic subtypes. 69% had TNM (8th edition) stage IV (A in 41%, B in 28%) and 26% had stage III (IIIA 8%, IIIB 10% and IIIC in 8%). Chemotherapy with or without radiotherapy (86%), tyrosine kinase inhibitors (6%) and immunotherapy (1%) were the common treatment modalities, while 10 patients did not receive any treatment. In whom response could be assessed (n=61), the best response achieved was partial response in 38%, stable disease in 49%, complete response in 5% and progressive disease in 8%. Of the subjects undergoing chemotherapy (n=102), 33 experienced grade 3 or 4 AE and 14 subjects had to discontinue chemotherapy before 4 cycles. ECOG PS improved to 0/1 in 22 (19.6%) subjects who underwent any form of treatment. The median survival of the study cohort was 250 days. On a multivariate analysis, the presence of brain metastases was associated with poor OS (HR [95% CI] 7.6 [1.4-41.6])


      Conclusions: Most of the Elderly patients with NSCLC and poor PS had an advanced stage at presentation. Majority tolerate chemotherapy well and some have an improvement in their PS. The presence of brain metastases is associated with a poor survival.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.